Free Newsletter
Merck's jobs axe is put to work
There's a lot of rumbling in the blogosphere about the Merck job-chopping block. Last fall Merck announced it would shed 6,800 jobs--and now, the drugmaker is lowering the boom. Or so we're told.
Derek Lowe at In the Pipeline is hearing firsthand from Merck folks that an across-the-board cutback in R&D is going on as we speak. Research types at all R&D sites are getting pink slips.
And with Merck and Schering-Plough destined to merge later this year, the job cuts are due to step up a notch. If the current round is part of the previously announced restructuring plan, they're just a warm-up for an expected 16,000 or so additional cuts. All told, Merck and Schering-Plough's workforce is expected to shrink by 15 percent.
- read the post at In The Pipeline
Related Articles:
Merck, Schering to cut 16,000 post-merger
Merck nabs Schering-Plough in $41.1B deal
Merck - Top 5 layoffs of 2008
Schering-Plough - Top 5 layoffs of 2008
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: